RE:Another company's phase 1a data readout plansA lot of words, not much substance.
SPCEO1 wrote: This is from a Piper report on another cancer stock - EPIX. Notice the willingness of the company to put forward a comprehensive review of their dose escalation trial.
Dose escalation update expected before end of 2Q. EPI-7386's Phase Ia doseescalation continues with patients currently being dosed at 1,000 mg QD, 800mg/dayadministered as 400 mg BID and 1,200 mg/day administered as 600 mg BID. EPIXindicated to us that the update is likely to come in the form of a company press release/investor call and would include all dose-escalation data to date including potentially themost recently initiated 600 mg BID cohort (albeit likely with limited follow-up). It willprovide a complete picture of safety/tolerability and clinical efficacy, as well as ctDNAanalyses, which it indicated has provided valuable insights into the disease biology inthese late-stage patients. It also noted that the amendment limiting the number of priorlines of therapy and the exclusion of patients with visceral metastases seems to haveeliminated overt neuroendocrine disease, but experience is still limited. The Phase Ibdose expansion is expected to initiate in 2H22 and could move forward with a coupledoses, with patient selection strategy the central remaining question. With the Ib portion,EPIX will also use Caris's whole transcriptome and whole exome sequencing platformto further characterize patient biological profiles